By the end of the year, FutureMeds plans to operate from 3 sites located in the biggest cities in Bulgaria.
Following successes in Poland and the United Kingdom, FutureMeds is expanding its Dedicated Research Site Network into Bulgaria, where, by the end of 2021, it will operate from 3 sites located in the biggest cities in the country.
Bulgaria is among the 20 most productive countries in the world for clinical trials, with the Bulgarian market currently valued at USD 330 million.
Recent improvements in the regulatory environment have alleviated roadblocks impeding the sector and the market has been growing steadily over the last 5 years.
The country offers great potential for Pharma and Contract Research Organizations and the presence of 3 FutureMeds sites will further strengthen the sector.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.